Is Aducanumab for LMICs? Promises and Challenges

Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA). A substantial proportion of patients with Alzheimer’s disease live in low- and middle-income countries...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Illangage P. C. Gunawardena, Thaarvena Retinasamy, Mohd. Farooq Shaikh
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Alzheimer’s disease aducanumab LMICs APOE burden of disease treatment cost Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/44cb328dbf49468a9766220ed27181b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44cb328dbf49468a9766220ed27181b2
record_format	dspace
spelling	oai:doaj.org-article:44cb328dbf49468a9766220ed27181b22021-11-25T16:59:22ZIs Aducanumab for LMICs? Promises and Challenges10.3390/brainsci111115472076-3425https://doaj.org/article/44cb328dbf49468a9766220ed27181b22021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1547https://doaj.org/toc/2076-3425Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA). A substantial proportion of patients with Alzheimer’s disease live in low- and middle-income countries (LMICs), and the debilitating effects of this disease exerts burdens on patients and caregivers in addition to the significant economic strains many nations bear. While the advantages of a disease-modifying therapy are clear in delaying the progression of disease to improve patient outcomes, aducanumab’s approval by the U.S. FDA was met with controversy for a plethora of reasons. This paper will provide precursory insights into aducanumab’s role, appropriateness, and cost-effectiveness in low- and middle-income countries. We extend some of the controversies associated with aducanumab, including the contradicting evidence from the two trials (EMERGE and ENGAGE) and the resources required to deliver the treatment safely and effectively to patients, among other key considerations.Illangage P. C. GunawardenaThaarvena RetinasamyMohd. Farooq ShaikhMDPI AGarticleAlzheimer’s diseaseaducanumabLMICsAPOEburden of diseasetreatment costNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1547, p 1547 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Alzheimer’s disease aducanumab LMICs APOE burden of disease treatment cost Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	Alzheimer’s disease aducanumab LMICs APOE burden of disease treatment cost Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Illangage P. C. Gunawardena Thaarvena Retinasamy Mohd. Farooq Shaikh Is Aducanumab for LMICs? Promises and Challenges
description	Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA). A substantial proportion of patients with Alzheimer’s disease live in low- and middle-income countries (LMICs), and the debilitating effects of this disease exerts burdens on patients and caregivers in addition to the significant economic strains many nations bear. While the advantages of a disease-modifying therapy are clear in delaying the progression of disease to improve patient outcomes, aducanumab’s approval by the U.S. FDA was met with controversy for a plethora of reasons. This paper will provide precursory insights into aducanumab’s role, appropriateness, and cost-effectiveness in low- and middle-income countries. We extend some of the controversies associated with aducanumab, including the contradicting evidence from the two trials (EMERGE and ENGAGE) and the resources required to deliver the treatment safely and effectively to patients, among other key considerations.
format	article
author	Illangage P. C. Gunawardena Thaarvena Retinasamy Mohd. Farooq Shaikh
author_facet	Illangage P. C. Gunawardena Thaarvena Retinasamy Mohd. Farooq Shaikh
author_sort	Illangage P. C. Gunawardena
title	Is Aducanumab for LMICs? Promises and Challenges
title_short	Is Aducanumab for LMICs? Promises and Challenges
title_full	Is Aducanumab for LMICs? Promises and Challenges
title_fullStr	Is Aducanumab for LMICs? Promises and Challenges
title_full_unstemmed	Is Aducanumab for LMICs? Promises and Challenges
title_sort	is aducanumab for lmics? promises and challenges
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/44cb328dbf49468a9766220ed27181b2
work_keys_str_mv	AT illangagepcgunawardena isaducanumabforlmicspromisesandchallenges AT thaarvenaretinasamy isaducanumabforlmicspromisesandchallenges AT mohdfarooqshaikh isaducanumabforlmicspromisesandchallenges
_version_	1718412771794616320

Is Aducanumab for LMICs? Promises and Challenges

Ejemplares similares